BUFFALO, N.Y. – A smartphone app that tracks palpitations in heart patients provides comparable performance to the 14-day event monitors that are the current standard of care, according to a ...

AliveCor’s latest attempt to revive its Apple Watch antitrust case fell short this week, with a federal appeals court ...

An antitrust lawsuit that AliveCor filed against Apple back in 2021 will not proceed, with the judge overseeing the case today filing a summary judgment in Apple's favor. The full ruling is under seal ...

Apple Inc.‘s win in a high profile antitrust battle with medical device company AliveCor Inc. over the Apple Watch’s heart ...

While the step counters and run tracker apps of the world get most of the attention, a growing number of apps in the marketplace are serving serious clinical needs. One is AliveCor‘s AliveECG app, ...

Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S. The Kardia Pro app is for clinical use. But ...

A new app is giving heart patients an emergency room in the palm of their hands. The AliveCor app acts as a “clinical grade” on-the-go EKG monitor, and a there’s a new international study to prove its ...

AliveCor, Inc. announced today the launch of the latest version of the AliveECG app, with two new FDA-cleared and CE-marked automated detectors that allow patients and physicians to focus on the ECGs ...

“For years I have struggled with my AF. Using the AliveCor Heart Monitor and app allows me to detect my AF episodes and easily track my medications and activities. I can simply share those results ...

Smartphone ECG maker AliveCor is partnering with Omron Healthcare to integrate blood pressure data into its mobile app, creating the first tool of its kind to help patients “paint a more complete ...

MOUNTAIN VIEW, Calif., Dec. 20, 2021 /PRNewswire/ -- AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced that KardiaMobile 6L, the most ...